Epstein-Barr virus latency antigen peptide-Major Histocompatibility Complex class I complex (EBV pMHC-I)

Peptide-MHC class I complexes presenting Epstein-Barr virus (EBV) latency antigens are molecular assemblies on the surface of cells that signal the presence of latent EBV infection or EBV-driven oncogenesis. These complexes consist of an 8-11 amino acid peptide derived from EBV latency proteins—such as Epstein-Barr nuclear antigen 1 (EBNA1) or Latent Membrane Proteins (LMP1, LMP2)—bound within the groove of a Major Histocompatibility Complex (MHC) class I molecule (Hislop et al., 2007, PubMed: 17591599). Their primary biological function is to facilitate immune surveillance by presenting intracellular viral antigens to the T-cell receptors (TCRs) of CD8+ cytotoxic T lymphocytes (Taylor et al., 2015, PubMed: 25708282). In the context of EBV-associated malignancies, such as nasopharyngeal carcinoma and post-transplant lymphoproliferative disorder (PTLD), these complexes are utilized as highly specific therapeutic targets. Drugs like Tabelecleucel and various TCR-engineered T-cell (TCR-T) therapies interact with these complexes to selectively eliminate malignant cells while sparing healthy tissue (Bollard & Heslop, 2016, PubMed: 27167065). However, therapeutic challenges include the potential for HLA downregulation by tumor cells to evade detection and the risk of off-target cross-reactivity with similar self-peptides. These complexes represent a cornerstone of precision immunotherapy for viral-driven cancers.

Other names

EBV peptide-HLA class I complexEBV pMHCEpstein-Barr virus antigen-MHC complexEBV-specific peptide-MHCEBV latency antigen-HLA complex

Recognition of the specific viral peptide-MHC complex by T-cell receptors (TCRs) or TCR-like molecules, triggering cytotoxic activity and apoptosis of the infected or malignant cell.